SheldonHPreskornMD
Psychiatry • Wichita, KSGeriatric Psychiatry, Pain Medicine
Professor, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine
Are you Dr. Preskorn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1001 N Minneapolis
Wichita, KS 67214Phone+1 316-293-2647Fax+1 316-293-1863
Summary
- Dr. Sheldon Preskorn, MD is a board certified psychiatrist in Wichita, Kansas. He is currently licensed to practice medicine in Kansas, Oklahoma, and Missouri. He is affiliated with Ascension Via Christi St. Francis and is a Professor at University of Kansas School of Medicine.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Psychiatry, 1976 - 1978
University of Kansas School of MedicineInternship, Transitional Year, 1975 - 1976- University of Kansas School of MedicineResidency, Pathology-Anatomic and Clinical, 1973 - 1974
- University of Kansas School of MedicineClass of 1974
Certifications & Licensure
KS State Medical License 1975 - 2025
OK State Medical License 2013 - 2016
MO State Medical License 1976 - 2014- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Minocycline and Aspirin in the Treatment of Bipolar Depression Start of enrollment: 2011 Sep 01
- Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Sep 12
- A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Start of enrollment: 2014 Mar 26
- Join now to see all
Publications & Presentations
PubMed
- 240 citationsEfficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Bli...Maggie Fedgchin, Madhukar H. Trivedi, Ella Daly, Rama Melkote, Rosanne Lane
The International Journal of Neuropsychopharmacology. 2019-10-01 - 138 citationsRandomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous a...Sheldon H. Preskorn, Matthew Macaluso, Do Vishaal Mehra, Gary Zammit, Joseph R. Moskal
Journal of Psychiatric Practice. 2015-03-01 - 45 citationsEffect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.Sheldon H Preskorn, Scott Zeller, Leslie Citrome, Jeffrey Finman, Joseph F Goldberg
JAMA. 2022-02-22
Press Mentions
BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York CityMay 13th, 2019
Antidepressant Trials Exclude Vast Majority of Depressed PatientsJuly 15th, 2015
Grant Support
- Central Adrenergic System And Blood Brain BarrierNational Institute Of Neurological Disorders And Stroke1985–1986
